Interestingly, our results showed that the risk of VTE in ROS1 rearrangements(ROS1+) patients is 2.63-fold greater than that in ROS1- patients, and the odds of VTE in ROS1+ lung cancer were higher than ALK+, EGFR+ and KRAS+ cohorts in the univariate analysis. This evidence concerns the gene ROS1 and lung cancer.